1
|
Natesan R, Dykstra AB, Banerjee A, Agrawal NJ. Heterogeneity in Disulfide Bond Reduction in IgG1 Antibodies Is Governed by Solvent Accessibility of the Cysteines. Antibodies (Basel) 2023; 12:83. [PMID: 38131805 PMCID: PMC10741012 DOI: 10.3390/antib12040083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2023] [Revised: 11/22/2023] [Accepted: 12/01/2023] [Indexed: 12/23/2023] Open
Abstract
We studied unpaired cysteine levels and disulfide bond susceptibility in four different γ-immunoglobulin antibodies using liquid chromatography-mass spectrometry. Our choice of differential alkylating agents ensures that the differential peaks are non-overlapping, thus allowing us to accurately quantify free cysteine levels. For each cysteine residue, we observed no more than 5% to be unpaired, and the free cysteine levels across antibodies were slightly higher in those containing lambda light chains. Interchain and hinge residues were highly susceptible to reducing stresses and showed a 100-1000-fold higher rate of reduction compared to intrachain cysteines. Estimations of the solvent-accessible surface for individual cysteines in IgG1, using an implicit all-atom molecular dynamics simulation, show that interchain and hinge cysteines have >1000-fold higher solvent accessibility compared to intrachain cysteines. Further analyses show that solvent accessibility and the rate of reduction are linearly correlated. Our work clearly establishes the fact that a cysteine's accessibility to the surrounding solvent is one of the primary determinants of its disulfide bond stability.
Collapse
Affiliation(s)
- Ramakrishnan Natesan
- Amgen Inc., Process Development, 360 Binney St., Cambridge, MA 02141, USA; (R.N.); (A.B.)
| | | | - Akash Banerjee
- Amgen Inc., Process Development, 360 Binney St., Cambridge, MA 02141, USA; (R.N.); (A.B.)
| | - Neeraj J. Agrawal
- Amgen Inc., Process Development, 360 Binney St., Cambridge, MA 02141, USA; (R.N.); (A.B.)
| |
Collapse
|
2
|
Spears RJ, Chudasama V. Recent advances in N- and C-terminus cysteine protein bioconjugation. Curr Opin Chem Biol 2023; 75:102306. [PMID: 37236135 DOI: 10.1016/j.cbpa.2023.102306] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2022] [Revised: 03/12/2023] [Accepted: 03/20/2023] [Indexed: 05/28/2023]
Abstract
Advances in the site-specific chemical modification of proteins, also referred to as protein bioconjugation, have proved instrumental in revolutionary approaches to designing new protein-based therapeutics. Of the sites available for protein modification, cysteine residues or the termini of proteins have proved especially popular owing to their favorable properties for site-specific modification. Strategies that, therefore, specifically target cysteine at the termini offer a combination of these favorable properties of cysteine and termini bioconjugation. In this review, we discuss these strategies with a particular focus on those reported recently and provide our opinion on the future direction of the field.
Collapse
Affiliation(s)
- Richard J Spears
- Department of Chemistry, University College London, 20 Gordon Street, London, UK
| | - Vijay Chudasama
- Department of Chemistry, University College London, 20 Gordon Street, London, UK.
| |
Collapse
|
3
|
Saporiti S, Laurenzi T, Guerrini U, Coppa C, Palinsky W, Benigno G, Palazzolo L, Ben Mariem O, Montavoci L, Rossi M, Centola F, Eberini I. Effect of Fc core fucosylation and light chain isotype on IgG1 flexibility. Commun Biol 2023; 6:237. [PMID: 36869088 PMCID: PMC9982779 DOI: 10.1038/s42003-023-04622-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2022] [Accepted: 02/21/2023] [Indexed: 03/05/2023] Open
Abstract
N-glycosylation plays a key role in modulating the bioactivity of monoclonal antibodies (mAbs), as well as the light chain (LC) isotype can influence their physicochemical properties. However, investigating the impact of such features on mAbs conformational behavior is a big challenge, due to the very high flexibility of these biomolecules. In this work we investigate, by accelerated molecular dynamics (aMD), the conformational behavior of two commercial immunoglobulins G1 (IgG1), representative of κ and λ LCs antibodies, in both their fucosylated and afucosylated forms. Our results show, through the identification of a stable conformation, how the combination of fucosylation and LC isotype modulates the hinge behavior, the Fc conformation and the position of the glycan chains, all factors potentially affecting the binding to the FcγRs. This work also represents a technological enhancement in the conformational exploration of mAbs, making aMD a suitable approach to clarify experimental results.
Collapse
Affiliation(s)
- Simona Saporiti
- Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via Balzaretti, 9, 20133, Milan, Italy
| | - Tommaso Laurenzi
- Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via Balzaretti, 9, 20133, Milan, Italy
| | - Uliano Guerrini
- Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via Balzaretti, 9, 20133, Milan, Italy
| | - Crescenzo Coppa
- Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Sezione di Chimica Generale e Organica "A. Marchesini", Via Venezian, 21, 20133, Milano, Italy
| | - Wolf Palinsky
- Biotech Development Programme, Merck Biopharma, Aubonne, Switzerland
| | - Giulia Benigno
- Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via Balzaretti, 9, 20133, Milan, Italy
| | - Luca Palazzolo
- Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via Balzaretti, 9, 20133, Milan, Italy
| | - Omar Ben Mariem
- Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via Balzaretti, 9, 20133, Milan, Italy
| | - Linda Montavoci
- Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via Balzaretti, 9, 20133, Milan, Italy
| | - Mara Rossi
- Global Analytical Pharmaceutical Science and Innovation, Merck Serono S.p.A., Rome, Italy
| | - Fabio Centola
- Global Analytical Pharmaceutical Science and Innovation, Merck Serono S.p.A., Rome, Italy.
| | - Ivano Eberini
- Dipartimento di Scienze Farmacologiche e Biomolecolari & DSRC, Università degli Studi di Milano, Via Balzaretti, 9, 20133, Milan, Italy
| |
Collapse
|
4
|
Spears RJ, Chrzastek A, Yap SY, Karu K, Aliev AE, Baker JR, Chudasama V. Unearthing the unique stability of thiophosphonium-C-terminal cysteine adducts on peptides and proteins. Chem Commun (Camb) 2022; 58:5359-5362. [PMID: 35394478 DOI: 10.1039/d2cc01090a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Herein we report a fundamental discovery on the use of tris(dialkylamino)phosphine reagents for peptide and protein modification. We discovered that C-terminal thiophosphonium species, which are uniquely stable, could be selectively and rapidly generated from their disulfide counterparts. In sharp and direct contrast, internal thiophosphonium species rapidly degrade to dehydroalanine. We demonstrate this remarkable chemoselectivity on a bis-cysteine model peptide, and the formation of a stable C-terminal-thiophosphonium adduct on an antibody fragment, as well as characterise the species in various small molecule/peptide studies.
Collapse
Affiliation(s)
- Richard J Spears
- UCL Department of Chemistry, 20 Gordon Street, London WC1H 0AJ, UK.
| | - Alina Chrzastek
- UCL Department of Chemistry, 20 Gordon Street, London WC1H 0AJ, UK.
| | - Steven Y Yap
- UCL Department of Chemistry, 20 Gordon Street, London WC1H 0AJ, UK.
| | - Kersti Karu
- UCL Department of Chemistry, 20 Gordon Street, London WC1H 0AJ, UK.
| | - Abil E Aliev
- UCL Department of Chemistry, 20 Gordon Street, London WC1H 0AJ, UK.
| | - James R Baker
- UCL Department of Chemistry, 20 Gordon Street, London WC1H 0AJ, UK.
| | - Vijay Chudasama
- UCL Department of Chemistry, 20 Gordon Street, London WC1H 0AJ, UK.
| |
Collapse
|
5
|
Nie S, Greer T, Huang X, Zheng X, Li N. Development of a simple non-reduced peptide mapping method that prevents disulfide scrambling of mAbs without affecting tryptic enzyme activity. J Pharm Biomed Anal 2021; 209:114541. [PMID: 34954467 DOI: 10.1016/j.jpba.2021.114541] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2021] [Revised: 12/16/2021] [Accepted: 12/17/2021] [Indexed: 11/27/2022]
Abstract
Non-reduced peptide mapping by liquid chromatography-mass spectrometry (LC-MS) analysis is a commonly used method for disulfide linkage characterization to assess structural integrity and quality of therapeutic monoclonal antibodies (mAbs). However, disulfide scrambling artifacts induced during sample preparation are often observed when basic pH and high temperatures are used during denaturation and digestion. To minimize disulfide scrambling artifacts, methods using various acidic pH conditions have been developed by multiple groups. However, lower pH conditions increase missed and non-specific cleavages, which complicates disulfide bond analysis because the majority of enzymes used in protein characterization are most efficient at alkaline pH. Here, we developed a non-reduced peptide mapping method for mAb characterization that minimizes disulfide scrambling at basic pH by adding an oxidizing agent, cystamine, and a low concentration of iodoacetamide (IAA) alkylating agent. Two human IgG1 mAbs, one with kappa light chain and another one with lambda light chain, were used as model proteins to develop and optimize the method. Using this novel method, disulfide scrambled peptides related to light chain-heavy chain (LC-HC) inter-disulfide disruption were significantly reduced with high reproducibility compared to conventional methods. Results demonstrated that the cystamine-added method is robust and minimizes disulfide scrambling artifacts produced during sample preparation.
Collapse
Affiliation(s)
- Song Nie
- Analytical Chemistry, Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, United States
| | - Tyler Greer
- Analytical Chemistry, Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, United States
| | - Xiaoxiao Huang
- Analytical Chemistry, Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, United States
| | - Xiaojing Zheng
- Analytical Chemistry, Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, United States.
| | - Ning Li
- Analytical Chemistry, Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, United States
| |
Collapse
|
6
|
Dong Q, Yan X, Liang Y, Markey SP, Sheetlin SL, Remoroza CA, Wallace WE, Stein SE. Comprehensive Analysis of Tryptic Peptides Arising from Disulfide Linkages in NISTmAb and Their Use for Developing a Mass Spectral Library. J Proteome Res 2021; 20:1612-1629. [PMID: 33555887 PMCID: PMC9278810 DOI: 10.1021/acs.jproteome.0c00823] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
![]()
This
work presents methods for identifying and then creating a
mass spectral library for disulfide-linked peptides originating from
the NISTmAb, a reference material of the humanized IgG1k monoclonal
antibody (RM 8671). Analyses involved both partially reduced and non-reduced
samples under neutral and weakly basic conditions followed by nanoflow
liquid chromatography tandem mass spectrometry (LC–MS/MS).
Spectra of peptides containing disulfide bonds are identified by both
MS1 ion and MS2 fragment ion data in order to completely map all the
disulfide linkages in the NISTmAb. This led to the detection of 383
distinct disulfide-linked peptide ions, arising from fully tryptic
cleavage, missed cleavage, irregular cleavage, complex Met/Trp oxidation
mixtures, and metal adducts. Fragmentation features of disulfide bonds
under low-energy collision dissociation were examined. These include
(1) peptide bond cleavage leaving disulfide bonds intact; (2) disulfide
bond cleavage, often leading to extensive fragmentation; and (3) double
cleavage products resulting from breakages of two peptide bonds or
both peptide and disulfide bonds. Automated annotation of various
complex MS/MS fragments enabled the identification of disulfide-linked
peptides with high confidence. Peptides containing each of the nine
native disulfide bonds were identified along with 86 additional disulfide
linkages arising from disulfide bond shuffling. The presence of shuffled
disulfides was nearly completely abrogated by refining digest conditions.
A curated spectral library of 702 disulfide-linked peptide spectra
was created from this analysis and is publicly available for free
download. Since all IgG1 antibodies have the same constant regions,
the resulting library can be used as a tool for facile identification
of “hard-to-find” disulfide-bonded peptides. Moreover,
we show that one may identify such peptides originating from IgG1
proteins in human serum, thereby serving as a means of monitoring
the completeness of protein reduction in proteomics studies. Data
are available via ProteomeXchange with identifier PXD023358.
Collapse
Affiliation(s)
- Qian Dong
- Biomolecular Measurement Division, National Institute of Standards and Technology, 100 Bureau Drive, Stop 8362, Gaithersburg, Maryland 20899, United States
| | - Xinjian Yan
- Biomolecular Measurement Division, National Institute of Standards and Technology, 100 Bureau Drive, Stop 8362, Gaithersburg, Maryland 20899, United States
| | - Yuxue Liang
- Biomolecular Measurement Division, National Institute of Standards and Technology, 100 Bureau Drive, Stop 8362, Gaithersburg, Maryland 20899, United States
| | - Sanford P Markey
- Biomolecular Measurement Division, National Institute of Standards and Technology, 100 Bureau Drive, Stop 8362, Gaithersburg, Maryland 20899, United States
| | - Sergey L Sheetlin
- Biomolecular Measurement Division, National Institute of Standards and Technology, 100 Bureau Drive, Stop 8362, Gaithersburg, Maryland 20899, United States
| | - Concepcion A Remoroza
- Biomolecular Measurement Division, National Institute of Standards and Technology, 100 Bureau Drive, Stop 8362, Gaithersburg, Maryland 20899, United States
| | - William E Wallace
- Biomolecular Measurement Division, National Institute of Standards and Technology, 100 Bureau Drive, Stop 8362, Gaithersburg, Maryland 20899, United States
| | - Stephen E Stein
- Biomolecular Measurement Division, National Institute of Standards and Technology, 100 Bureau Drive, Stop 8362, Gaithersburg, Maryland 20899, United States
| |
Collapse
|
7
|
Mastrangeli R, Audino MC, Palinsky W, Broly H, Bierau H. The Formidable Challenge of Controlling High Mannose-Type N-Glycans in Therapeutic mAbs. Trends Biotechnol 2020; 38:1154-1168. [DOI: 10.1016/j.tibtech.2020.05.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Revised: 05/18/2020] [Accepted: 05/19/2020] [Indexed: 02/08/2023]
|
8
|
Lieu R, Antonysamy S, Druzina Z, Ho C, Kang NR, Pustilnik A, Wang J, Atwell S. Rapid and robust antibody Fab fragment crystallization utilizing edge-to-edge beta-sheet packing. PLoS One 2020; 15:e0232311. [PMID: 32915778 PMCID: PMC7485759 DOI: 10.1371/journal.pone.0232311] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Accepted: 08/12/2020] [Indexed: 01/09/2023] Open
Abstract
Antibody therapeutics are one of the most important classes of drugs. Antibody structures have become an integral part of predicting the behavior of potential therapeutics, either directly or as the basis of modeling. Structures of Fab:antigen complexes have even greater value. While the crystallization and structure determination of Fabs is easy relative to many other protein classes, especially membrane proteins, broad screening and optimization of crystalline hits is still necessary. Through a comprehensive review of rabbit Fab crystal contacts and their incompatibility with human Fabs, we identified a small secondary structural element from the rabbit light chain constant domain potentially responsible for hindering the crystallization of human Fabs. Upon replacing the human kappa constant domain FG loop (HQGLSSP) with the two residue shorter rabbit loop (QGTTS), we dramatically improved the crystallization of human Fabs and Fab:antigen complexes. Our design, which we call "Crystal Kappa", enables rapid crystallization of human fabs and fab complexes in a broad range of conditions, with less material in smaller screens or from dilute solutions.
Collapse
Affiliation(s)
- Ricky Lieu
- Biotechnology Discovery Research, Applied Molecular Evolution, Eli Lilly and Company, San Diego, CA, United States of America
| | - Stephen Antonysamy
- Discovery Chemistry Research and Technologies, Eli Lilly and Company Corporate Center, Indianapolis, IN, United States of America
| | - Zhanna Druzina
- Discovery Chemistry Research and Technologies, Eli Lilly and Company Corporate Center, Indianapolis, IN, United States of America
| | - Carolyn Ho
- Biotechnology Discovery Research, Applied Molecular Evolution, Eli Lilly and Company, San Diego, CA, United States of America
| | - N. Rebecca Kang
- Biotechnology Discovery Research, Applied Molecular Evolution, Eli Lilly and Company, San Diego, CA, United States of America
| | - Anna Pustilnik
- Discovery Chemistry Research and Technologies, Eli Lilly and Company Corporate Center, Indianapolis, IN, United States of America
| | - Jing Wang
- Discovery Chemistry Research and Technologies, Eli Lilly and Company Corporate Center, Indianapolis, IN, United States of America
| | - Shane Atwell
- Biotechnology Discovery Research, Applied Molecular Evolution, Eli Lilly and Company, San Diego, CA, United States of America
- * E-mail:
| |
Collapse
|
9
|
Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity. J Pharm Sci 2019; 109:233-246. [PMID: 31348937 PMCID: PMC6941225 DOI: 10.1016/j.xphs.2019.07.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2019] [Revised: 07/08/2019] [Accepted: 07/17/2019] [Indexed: 01/06/2023]
Abstract
The broadly neutralizing anti-HIV antibody, 10-1074, is a highly somatically hypermutated IgG1 being developed for prophylaxis in sub-Saharan Africa. A series of algorithms were applied to identify potentially destabilizing residues in the framework of the Fv region. Of 17 residues defined, a variant was identified encompassing 1 light and 3 heavy chain residues, with significantly increased conformational stability while maintaining full neutralization activity. Central to the stabilization was the replacement of the heavy chain residue T108 with R108 at the base of the CDR3 loop which allowed for the formation of a nascent salt bridge with heavy chain residue D137. Three additional mutations were necessary to confer increased conformational stability as evidenced by differential scanning fluorimetry and isothermal chemical unfolding. In addition, we observed increased stability during low pH incubation in which 40% of the parental monomer aggregated while the combinatorial variant showed no increase in aggregation. Incubation of the variant at 100 mg/mL for 6 weeks at 40°C showed a 9-fold decrease in subvisible particles ≥2 μm relative to the parental molecule. Stability-based designs have also translated to improved pharmacokinetics. Together, these data show that increasing conformational stability of the Fab can have profound effects on the manufacturability and long-term stability of a monoclonal antibody.
Collapse
|
10
|
Han L, Liu C, Qi H, Zhou J, Wen J, Wu D, Xu D, Qin M, Ren J, Wang Q, Long L, Liu Y, Chen I, Yuan X, Lu Y, Kang C. Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2019; 31:e1805697. [PMID: 30773720 DOI: 10.1002/adma.201805697] [Citation(s) in RCA: 64] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/02/2018] [Revised: 12/08/2018] [Indexed: 06/09/2023]
Abstract
As an essential component of immunotherapy, monoclonal antibodies (mAbs) have emerged as a class of powerful therapeutics for treatment of a broad range of diseases. For central nervous system (CNS) diseases, however, the efficacy remains limited due to their inability to enter the CNS. A platform technology is reported here that enables effective delivery of mAbs to the CNS for brain tumor therapy. This is achieved by encapsulating the mAbs within nanocapsules that contain choline and acetylcholine analogues; such analogues facilitate the penetration of the nanocapsules through the brain-blood barrier and the delivery of mAbs to tumor sites. This platform technology uncages the therapeutic power of mAbs for various CNS diseases that remain poorly treated.
Collapse
Affiliation(s)
- Lei Han
- Department of Neurosurgery, Tianjin Medical University General Hospital; Key Laboratory of Neurotrauma, Variation, and Regeneration, Ministry of Education and Tianjin Municipal Government, Tianjin Neurological Institute, Tianjin, 300052, China
| | - Chaoyong Liu
- Department of Neurosurgery, Tianjin Medical University General Hospital; Key Laboratory of Neurotrauma, Variation, and Regeneration, Ministry of Education and Tianjin Municipal Government, Tianjin Neurological Institute, Tianjin, 300052, China
- College of Life Science and Technology, and Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing, 100029, China
| | - Hongzhao Qi
- School of Materials Science Engineering, Tianjin University, Tianjin, 300350, China
| | - Junhu Zhou
- Department of Neurosurgery, Tianjin Medical University General Hospital; Key Laboratory of Neurotrauma, Variation, and Regeneration, Ministry of Education and Tianjin Municipal Government, Tianjin Neurological Institute, Tianjin, 300052, China
| | - Jing Wen
- Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, UCLA AIDS Institute, Los Angeles, CA 90095, USA
| | - Di Wu
- Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, CA 90095, USA
| | - Duo Xu
- Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, CA 90095, USA
| | - Meng Qin
- College of Life Science and Technology, and Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing, 100029, China
| | - Jie Ren
- Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, CA 90095, USA
| | - Qixue Wang
- Department of Neurosurgery, Tianjin Medical University General Hospital; Key Laboratory of Neurotrauma, Variation, and Regeneration, Ministry of Education and Tianjin Municipal Government, Tianjin Neurological Institute, Tianjin, 300052, China
| | - Lixia Long
- School of Materials Science Engineering, Tianjin University, Tianjin, 300350, China
| | - Yang Liu
- Key Laboratory of Functional Polymer Materials of Ministry of Education, Institute of Polymer Chemistry, College of Chemistry, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, 300071, China
| | - Irvin Chen
- Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, UCLA AIDS Institute, Los Angeles, CA 90095, USA
| | - Xubo Yuan
- School of Materials Science Engineering, Tianjin University, Tianjin, 300350, China
| | - Yunfeng Lu
- Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, CA 90095, USA
| | - Chunsheng Kang
- Department of Neurosurgery, Tianjin Medical University General Hospital; Key Laboratory of Neurotrauma, Variation, and Regeneration, Ministry of Education and Tianjin Municipal Government, Tianjin Neurological Institute, Tianjin, 300052, China
| |
Collapse
|
11
|
Reinhart D, Damjanovic L, Kaisermayer C, Sommeregger W, Gili A, Gasselhuber B, Castan A, Mayrhofer P, Grünwald-Gruber C, Kunert R. Bioprocessing of Recombinant CHO-K1, CHO-DG44, and CHO-S: CHO Expression Hosts Favor Either mAb Production or Biomass Synthesis. Biotechnol J 2018; 14:e1700686. [PMID: 29701329 DOI: 10.1002/biot.201700686] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2018] [Revised: 03/26/2018] [Indexed: 01/02/2023]
Abstract
Chinese hamster ovary (CHO) cells comprise a variety of lineages including CHO-DXB11, CHO-K1, CHO-DG44, and CHO-S. Despite all CHO cell lines sharing a common ancestor, extensive mutagenesis, and clonal selection has resulted in substantial genetic heterogeneity among them. Data from sequencing show that different genes are missing in individual CHO cell lines and each cell line harbors a unique set of mutations with relevance to the bioprocess. However, not much literature is available about the influence of genetic differences of CHO on the performance of bioprocess operations. In this study, the host cell-specific differences among three widely used CHO cell lines (CHO-K1, CHO-S, and CHO-DG44) and recombinantly expressed the same monoclonal antibody (mAb) in an isogenic format by using bacterial artificial chromosomes (BACs) as transfer vector in all cell lines is examined. Cell-specific growth and product formation are studied in batch, fed-batch, and semi-continuous perfusion cultures. Further, two different cell culture media are used to investigate their effects. The authors find CHO cell line-specific preferences for mAb production or biomass synthesis that are determined by the host cell line. Additionally, quality attributes of the expressed mAb are influenced by the host cell line and media.
Collapse
Affiliation(s)
- David Reinhart
- Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Muthgasse 11, 1190 Vienna, Austria
| | - Lukas Damjanovic
- Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Muthgasse 11, 1190 Vienna, Austria
| | | | - Wolfgang Sommeregger
- Bilfinger Industrietechnik Salzburg GmbH, Urstein Nord 31, 5412 Puch bei Hallein, Austria
| | - Andreas Gili
- Polymun Scientific Immunbiologische Forschung GmbH, Donaustraße 99, 3400 Klosterneuburg, Austria
| | - Bernhard Gasselhuber
- Department of Chemistry, University of Natural Resources and Life Sciences, Vienna, Muthgasse 18, 1190 Vienna, Austria
| | - Andreas Castan
- GE Healthcare Life Sciences AB, Björkgatan 30, 75184 Uppsala, Sweden
| | - Patrick Mayrhofer
- Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Muthgasse 11, 1190 Vienna, Austria
| | - Clemens Grünwald-Gruber
- Department of Chemistry, University of Natural Resources and Life Sciences, Vienna, Muthgasse 18, 1190 Vienna, Austria
| | - Renate Kunert
- Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Muthgasse 11, 1190 Vienna, Austria
| |
Collapse
|
12
|
Wozniak-Knopp G, Stadlmayr G, Perthold JW, Stadlbauer K, Gotsmy M, Becker S, Rüker F. An antibody with Fab-constant domains exchanged for a pair of CH3 domains. PLoS One 2018; 13:e0195442. [PMID: 29630643 PMCID: PMC5891013 DOI: 10.1371/journal.pone.0195442] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2017] [Accepted: 03/22/2018] [Indexed: 12/29/2022] Open
Abstract
We have designed a complete antibody-like construct where the CH1 and Cκ domains are exchanged for a pair of the CH3 domains and efficient pairing of the heavy and light variable domain is achieved using “Knobs-into-Holes” strategy. This construct, composed of only naturally occurring immunoglobulin sequences without artificial linkers, expressed at a high level in mammalian cells, however exhibited low solubility. Rational mutagenesis aimed at the amino acid residues located at the interface of the variable domains and the exchanged CH3 domains was applied to improve the biophysical properties of the molecule. The domain-exchanged construct, including variable domains of the HER2/neu specific antibody trastuzumab, was able to bind to the surface of the strongly HER2/neu positive cell line SK-BR3 4-fold weaker than trastuzumab, but could nevertheless incite a more potent response in an antibody-dependent cell cytotoxicity (ADCC) reporter assay with FcγRIIIa-overexpressing T-cells. This could be explained with a stronger binding to the FcγRIIIa. Importantly, the novel construct could mediate a specific ADCC effect with natural killer cells similar to the parental antibody.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/chemistry
- Antibodies, Monoclonal/genetics
- Antibodies, Monoclonal/immunology
- Antibody-Dependent Cell Cytotoxicity
- Cell Line
- Humans
- Immunoglobulin Constant Regions/chemistry
- Immunoglobulin Constant Regions/genetics
- Immunoglobulin Constant Regions/immunology
- Immunoglobulin Fab Fragments/chemistry
- Immunoglobulin Fab Fragments/genetics
- Immunoglobulin Fab Fragments/immunology
- Immunoglobulin G/chemistry
- Immunoglobulin G/genetics
- Immunoglobulin G/immunology
- Killer Cells, Natural/immunology
- Models, Molecular
- Mutagenesis, Site-Directed
- Protein Domains
- Protein Engineering
- Receptor, ErbB-2/immunology
- Receptors, IgG/chemistry
- Receptors, IgG/genetics
- Receptors, IgG/immunology
- Recombinant Proteins/chemistry
- Recombinant Proteins/genetics
- Recombinant Proteins/immunology
- Trastuzumab/chemistry
- Trastuzumab/genetics
- Trastuzumab/immunology
Collapse
Affiliation(s)
- Gordana Wozniak-Knopp
- Christian Doppler Laboratory for Innovative Immunotherapeutics, Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), Vienna, Austria
- * E-mail:
| | - Gerhard Stadlmayr
- Christian Doppler Laboratory for Innovative Immunotherapeutics, Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), Vienna, Austria
| | - Jan Walther Perthold
- Institute of Molecular Modeling and Simulation, Department of Material Sciences, University of Natural Resources and Life Sciences (BOKU), Vienna, Austria
| | - Katharina Stadlbauer
- Christian Doppler Laboratory for Innovative Immunotherapeutics, Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), Vienna, Austria
| | - Mathias Gotsmy
- Christian Doppler Laboratory for Innovative Immunotherapeutics, Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), Vienna, Austria
| | - Stefan Becker
- Protein Engineering and Antibody Technologies, Merck KGaA, Darmstadt, Germany
| | - Florian Rüker
- Christian Doppler Laboratory for Innovative Immunotherapeutics, Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), Vienna, Austria
| |
Collapse
|
13
|
Dimasi N, Fleming R, Sachsenmeier KF, Bezabeh B, Hay C, Wu J, Sult E, Rajan S, Zhuang L, Cariuk P, Buchanan A, Bowen MA, Wu H, Gao C. Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain. MAbs 2017; 9:438-454. [PMID: 28055299 DOI: 10.1080/19420862.2016.1277301] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
We developed an IgG1 domain-tethering approach to guide the correct assembly of 2 light and 2 heavy chains, derived from 2 different antibodies, to form bispecific monovalent antibodies in IgG1 format. We show here that assembling 2 different light and heavy chains by sequentially connecting them with protease-cleavable polypeptide linkers results in the generation of monovalent bispecific antibodies that have IgG1 sequence, structure and functional properties. This approach was used to generate a bispecific monovalent antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor that: 1) can be produced and purified using standard IgG1 techniques; 2) exhibits stability and structural features comparable to IgG1; 3) binds both targets simultaneously; and 4) has potent anti-tumor activity. Our strategy provides new engineering opportunities for bispecific antibody applications, and, most importantly, overcomes some of the limitations (e.g., half-antibody and homodimer formation, light chains mispairing, multi-step purification), inherent with some of the previously described IgG1-based bispecific monovalent antibodies.
Collapse
Affiliation(s)
- Nazzareno Dimasi
- a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA
| | - Ryan Fleming
- a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA
| | | | - Binyam Bezabeh
- a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA
| | - Carl Hay
- c Oncology Research, MedImmune , Gaithersburg , MD , USA
| | - Jincheng Wu
- d Research Bioinformatics, MedImmune , Gaithersburg , MD , USA
| | - Erin Sult
- c Oncology Research, MedImmune , Gaithersburg , MD , USA
| | - Saravanan Rajan
- a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA
| | - Li Zhuang
- a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA
| | - Peter Cariuk
- e Antibody Discovery and Protein Engineering, MedImmune , Cambridge , UK
| | - Andrew Buchanan
- e Antibody Discovery and Protein Engineering, MedImmune , Cambridge , UK
| | - Michael A Bowen
- a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA
| | - Herren Wu
- a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA
| | - Changshou Gao
- a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA
| |
Collapse
|
14
|
Shen Y, Zeng L, Novosyadlyy R, Forest A, Zhu A, Korytko A, Zhang H, Eastman SW, Topper M, Hindi S, Covino N, Persaud K, Kang Y, Burtrum D, Surguladze D, Prewett M, Chintharlapalli S, Wroblewski VJ, Shen J, Balderes P, Zhu Z, Snavely M, Ludwig DL. A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation. MAbs 2016; 7:931-45. [PMID: 26073904 PMCID: PMC4623440 DOI: 10.1080/19420862.2015.1055442] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Bi-specific antibodies (BsAbs), which can simultaneously block 2 tumor targets, have emerged as promising therapeutic alternatives to combinations of individual monoclonal antibodies. Here, we describe the engineering and development of a novel, human bi-functional antibody-receptor domain fusion molecule with ligand capture (bi-AbCap) through the fusion of the domain 2 of human vascular endothelial growth factor receptor 1 (VEGFR1) to an antibody directed against insulin-like growth factor - type I receptor (IGF-IR). The bi-AbCap possesses excellent stability and developability, and is the result of minimal engineering. Beyond potent neutralizing activities against IGF-IR and VEGF, the bi-AbCap is capable of cross-linking VEGF to IGF-IR, leading to co-internalization and degradation of both targets by tumor cells. In multiple mouse xenograft tumor models, the bi-AbCap improves anti-tumor activity over individual monotherapies. More importantly, it exhibits superior inhibition of tumor growth, compared with the combination of anti-IGF-IR and anti-VEGF therapies, via powerful blockade of both direct tumor cell growth and tumor angiogenesis. The unique "capture-for-degradation" mechanism of the bi-AbCap is informative for the design of next-generation bi-functional anti-cancer therapies directed against independent signaling pathways. The bi-AbCap design represents an alternative approach to the creation of dual-targeting antibody fusion molecules by taking advantage of natural receptor-ligand interactions.
Collapse
Affiliation(s)
- Yang Shen
- a Antibody Technology; Eli Lilly and Company ; New York , NY USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Spooner J, Keen J, Nayyar K, Birkett N, Bond N, Bannister D, Tigue N, Higazi D, Kemp B, Vaughan T, Kippen A, Buchanan A. Evaluation of strategies to control Fab light chain dimer during mammalian expression and purification: A universal one-step process for purification of correctly assembled Fab. Biotechnol Bioeng 2015; 112:1472-7. [PMID: 25619171 DOI: 10.1002/bit.25550] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2014] [Revised: 01/06/2015] [Accepted: 01/13/2015] [Indexed: 01/19/2023]
Abstract
Fabs are an important class of antibody fragment as both research reagents and therapeutic agents. There are a plethora of methods described for their recombinant expression and purification. However, these do not address the issue of excessive light chain production that forms light chain dimers nor do they describe a universal purification strategy. Light chain dimer impurities and the absence of a universal Fab purification strategy present persistent challenges for biotechnology applications using Fabs, particularly around the need for bespoke purification strategies. This study describes methods to address light chain dimer formation during Fab expression and identifies a novel CH 1 affinity resin as a simple and efficient one-step purification for correctly assembled Fab.
Collapse
Affiliation(s)
| | - Jenny Keen
- MedImmune, Granta Park, Cambridge, United Kingdom
| | | | - Neil Birkett
- MedImmune, Granta Park, Cambridge, United Kingdom
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Wiggins B, Liu-Shin L, Yamaguchi H, Ratnaswamy G. Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates. J Pharm Sci 2015; 104:1362-72. [PMID: 25631158 DOI: 10.1002/jps.24338] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2014] [Revised: 12/04/2014] [Accepted: 12/05/2014] [Indexed: 12/29/2022]
Abstract
Two US FDA-approved antibody-drug conjugates (ADCs; Kadcyla(®) and Adcetris(®) ) have accelerated clinical interest in the potential of targeted cancer therapeutics as the next generation of oncology drugs that are designed to increase efficacy while reducing overall toxicity. Thiol conjugates are produced by partial reduction of the interchain disulfides, followed by conjugation with a drug-linker, resulting in a heterogeneous mix of molecules that differ with respect to the site of conjugation and the number of drugs per antibody. ADCs that have been characterized in this class have an immunoglobulin G1 (IgG1) framework and there is little information available on IgG2 ADCs. As IgG1s and IgG2s differ in the number of disulfides and molecular conformations, each subclass could lead to unique combinations of possible conjugation sites. We conducted in-depth characterization of two ADCs, an IgG1 and an IgG2 conjugated to monomethyl auristatin E. The results demonstrate that the IgG1 monoclonal antibodies favor conjugation to the cysteines between the light and heavy chains, whereas IgG2s demonstrate preference for the hinge region cysteines. The drug-loading distribution and conjugation sites of ADCs have been reported to influence pharmacokinetics, toxicity, and clearance. Therefore, an understanding of the conjugation profiles is important for the selection and engineering of ADCs.
Collapse
Affiliation(s)
- Brian Wiggins
- Analytical and Formulation Development, Agensys, Inc., Santa Monica, California, 90404
| | | | | | | |
Collapse
|